Cargando…
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer
PURPOSE: Adoptively transferred, ex vivo expanded multi-antigen-targeted T cells (multiTAA-T) represent a new, potentially effective, and nontoxic therapeutic approach for patients with breast cancer (BC). In this first-in-human trial, we investigated the safety and clinical effects of administering...
Autores principales: | Hoyos, Valentina, Vasileiou, Spyridoula, Kuvalekar, Manik, Watanabe, Ayumi, Tzannou, Ifigeneia, Velazquez, Yovana, French-Kim, Matthew, Leung, Wingchi, Lulla, Suhasini, Robertson, Catherine, Foreman, Claudette, Wang, Tao, Bulsara, Shaun, Lapteva, Natalia, Grilley, Bambi, Ellis, Matthew, Osborne, Charles Kent, Coscio, Angela, Nangia, Julie, Heslop, Helen E., Rooney, Cliona M., Vera, Juan F., Lulla, Premal, Rimawi, Mothaffar, Leen, Ann M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290161/ https://www.ncbi.nlm.nih.gov/pubmed/35860837 http://dx.doi.org/10.1177/17588359221107113 |
Ejemplares similares
-
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients
por: Vasileiou, Spyridoula, et al.
Publicado: (2022) -
Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High-Risk Patients with COVID-19
por: Vasileiou, Spyridoula, et al.
Publicado: (2021) -
37. Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T Cells Demonstrate Reactivity Against Emerging Variant Strains
por: Vasileiou, Spyridoula, et al.
Publicado: (2021) -
Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19
por: Vasileiou, Spyridoula, et al.
Publicado: (2020) -
Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections
por: Vasileiou, Spyridoula, et al.
Publicado: (2020)